<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35125343</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1437-7780</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>28</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</Title>
          <ISOAbbreviation>J Infect Chemother</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Infliximab treatment for refractory COVID-19-associated multisystem inflammatory syndrome in a Japanese child.</ArticleTitle>
        <Pagination>
          <StartPage>814</StartPage>
          <EndPage>818</EndPage>
          <MedlinePgn>814-818</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jiac.2022.01.011</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1341-321X(22)00023-X</ELocationID>
        <Abstract>
          <AbstractText>Patients with multisystem inflammatory syndrome in children (MIS-C) can develop clinical features resembling Kawasaki disease (KD). A full picture of MIS-C in East Asia which has higher incidence of KD than other regions remains unclear. We report on a 15-year-old Japanese boy with refractory MIS-C who was successfully treated with infliximab. A Japanese boy who was diagnosed with coronavirus disease 2019 (COVID-19) before a month developed MIS-C with fulfilling six principal symptoms of KD. Laboratory data showed extreme hyperferritinemia (11,404 ng/mL), besides lymphopenia and thrombocytopenia. The patient was refractory to initial therapy with intravenous immunoglobulin (IVIG; 2 g/kg), aspirin, and prednisolone. He was therefore administered a second IVIG (2 g/kg) and infliximab (5 mg/kg) on days 7 and 8 from the onset of fever, respectively, which resulted in an improvement of clinical symptoms. Only four Japanese cases with MIS-C were reported and all of them were responsive to IVIG. The hyperferritinemia in this case was distinctive from previously reported MIS-C cases in Japan and other cohorts and may be associated with refractoriness to IVIG therapy. Marked elevation of circulating ferritin levels is known to be induced by tumor necrosis factor-α, which plays a key role in the pathogenesis of both KD and MIS-C. Thus, for MIS-C patients with hyperferritinemia, early intervention with adjunctive infliximab may induce a more rapid resolution of inflammation and improve outcome. Because MIS-C may be heterogeneous with respect to immunopathology, genetic background, clinical phenotypes and response to therapies, optimized treatment strategies according to immunopathogenesis are required.</AbstractText>
          <CopyrightInformation>Copyright © 2022 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yamaguchi</LastName>
            <ForeName>Yohei</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Takasawa</LastName>
            <ForeName>Kei</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan. Electronic address: ktakasawa.ped@tmd.ac.jp.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Irabu</LastName>
            <ForeName>Hitoshi</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Lifetime Clinical Immunology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hiratoko</LastName>
            <ForeName>Kanako</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, Nerima Hikarigaoka Hospital, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ichigi</LastName>
            <ForeName>Yosuke</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hirata</LastName>
            <ForeName>Ko</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tamura</LastName>
            <ForeName>Yumie</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Murakoshi</LastName>
            <ForeName>Miki</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yamashita</LastName>
            <ForeName>Motoi</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nakatani</LastName>
            <ForeName>Hisae</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shimoda</LastName>
            <ForeName>Masuhiro</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, Nerima Hikarigaoka Hospital, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ishii</LastName>
            <ForeName>Taku</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Udagawa</LastName>
            <ForeName>Tomohiro</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shimizu</LastName>
            <ForeName>Masaki</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Child Health and Development, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kanegane</LastName>
            <ForeName>Hirokazu</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Child Health and Development, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Morio</LastName>
            <ForeName>Tomohiro</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>01</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Infect Chemother</MedlineTA>
        <NlmUniqueID>9608375</NlmUniqueID>
        <ISSNLinking>1341-321X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016756">Immunoglobulins, Intravenous</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>B72HH48FLU</RegistryNumber>
          <NameOfSubstance UI="D000069285">Infliximab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <SupplMeshList>
        <SupplMeshName Type="Disease" UI="C000705967">pediatric multisystem inflammatory disease, COVID-19 related</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003240" MajorTopicYN="Y">Connective Tissue Diseases</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000085583" MajorTopicYN="Y">Hyperferritinemia</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016756" MajorTopicYN="N">Immunoglobulins, Intravenous</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069285" MajorTopicYN="N">Infliximab</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009080" MajorTopicYN="Y">Mucocutaneous Lymph Node Syndrome</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018746" MajorTopicYN="N">Systemic Inflammatory Response Syndrome</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">COVID-19</Keyword>
        <Keyword MajorTopicYN="N">Hyperinflammation</Keyword>
        <Keyword MajorTopicYN="N">Infliximab</Keyword>
        <Keyword MajorTopicYN="N">Multisystem inflammatory syndrome in children</Keyword>
      </KeywordList>
      <CoiStatement>Hitoshi Irabu: Tokyo Medical and Dental University (TMDU) received unrestricted research grants for Ayumi Pharmaceutical Corporation, Chugai Pharmaceutical Co., Ltd., CSL BehringCSL Behring K. K., Japan Blood Products Organization, UCB Japan Co. Ltd., with TMDU paid the salary of Hitoshi Irabu. All other authors have declared no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>7</Day>
          <Hour>5</Hour>
          <Minute>26</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35125343</ArticleId>
        <ArticleId IdType="pmc">PMC8784439</ArticleId>
        <ArticleId IdType="doi">10.1016/j.jiac.2022.01.011</ArticleId>
        <ArticleId IdType="pii">S1341-321X(22)00023-X</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Riphagen S., Gomez X., Gonzalez-Martinez C., Wilkinson N., Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020;395:1607–1608.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7204765</ArticleId>
            <ArticleId IdType="pubmed">32386565</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Multisystem inflammatory syndrome in children and adolescents with COVID-19 Scientific Brief. World Health Organization; 15 May 2020. https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19 Published.</Citation>
        </Reference>
        <Reference>
          <Citation>Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19) Health Alert Network (HAN); 14 May 2020. https://emergency.cdc.gov/han/2020/han00432.asp Published.</Citation>
        </Reference>
        <Reference>
          <Citation>Multisystem inflammatory syndrome in children (MIS-C) interim guidance. American academy of Pediatrics; 15 November 2021. https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/multisystem-inflammatory-syndrome-in-children-mis-c-interim-guidance/ Updated.</Citation>
        </Reference>
        <Reference>
          <Citation>Harwood R., Allin B., Jones C.E., Whittaker E., Ramnarayan P., Ramanan A.V., et al.  Lancet Child Adolesc Health. 2021;5:133–141.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7500943</ArticleId>
            <ArticleId IdType="pubmed">32956615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoste L., Van Paemel R., Haerynck F. Multisystem inflammatory syndrome in children related to COVID-19: a systematic review. Eur J Pediatr. 2021;180:2019–2034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7890544</ArticleId>
            <ArticleId IdType="pubmed">33599835</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guimarães D., Pissarra R., Reis-Melo A., Guimarães H. Multisystem inflammatory syndrome in children (MISC): a systematic review. Int J Clin Pract. 2021</Citation>
        </Reference>
        <Reference>
          <Citation>Yasuhara J., Watanabe K., Takagi H., Sumitomo N., Kuno T. COVID-19 and multisystem inflammatory syndrome in children: a systematic review and meta-analysis. Pediatr Pulmonol. 2021;56:837–848.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8013394</ArticleId>
            <ArticleId IdType="pubmed">33428826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Radia T., Williams N., Agrawal P., Harman K., Weale J., Cook J., et al.  Multi-system inflammatory syndrome in children &amp; adolescents (MIS-C): a systematic review of clinical features and presentation. Paediatr Respir Rev. 2021;38:51–57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7417920</ArticleId>
            <ArticleId IdType="pubmed">32891582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uehara R., Belay E.D. Epidemiology of Kawasaki disease in Asia, Europe, and the United States. J Epidemiol. 2012;22:79–85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3798585</ArticleId>
            <ArticleId IdType="pubmed">22307434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCrindle B.W., Rowley A.H., Newburger J.W., Burns J.C., Bolger A.F., Gewitz M., et al.  Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135:e927–e999.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28356445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kobayashi T., Ayusawa M., Suzuki H., Abe J., Ito S., Kato T., et al.  Revision of diagnostic guidelines for Kawasaki disease (6th revised edition) Pediatr Int. 2020;62:1135–1138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33001522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guidance: paediatric multisystem inflammatory syndrome temporally associated with COVID-19. Health RCoPaC; 2020. https://www.rcpch.ac.uk/resources/paediatric-multisystem-inflammatory-syndrome-temporally-associated-covid-19-pims-guidance</Citation>
        </Reference>
        <Reference>
          <Citation>Miura M., Ayusawa M., Ito SIkeda T., Kanai T., Kobayashi T., et al.  The guidelines on acute stage Kawasaki disease treatment (in Japanese) Ped Cardiol Card Surg. 2020;36 S1.1‒S1.29.</Citation>
        </Reference>
        <Reference>
          <Citation>Clinical consensus statement for multisystem inflammatory syndrome in children (MIS-C/PIMS) Japan Pediatric Society; 19 May 2021. https://www.jpeds.or.jp/uploads/files/202105120_mis-c_st.pdf Published.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhou C., Zhao Y., Wang X., Huang Y., Tang X., Tang L. Laboratory parameters between multisystem inflammatory syndrome in children and Kawasaki disease. Pediatr Pulmonol. 2021 doi: 10.1002/ppul.25687.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ppul.25687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee M.S., Liu Y.C., Tsai C.C., Hsu J.H., Wu J.R. Similarities and differences between COVID-19-related multisystem inflammatory syndrome in children and Kawasaki disease. Front Pediatr. 2021;9:640118.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8249705</ArticleId>
            <ArticleId IdType="pubmed">34222140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Esteve-Sole A., Anton J., Pino-Ramirez R.M., Sanchez-Manubens J., Fumadó V., Fortuny C., et al.  Similarities and differences between the immunopathogenesis of COVID-19-related pediatric multisystem inflammatory syndrome and Kawasaki disease. J Clin Invest. 2021;131</Citation>
        </Reference>
        <Reference>
          <Citation>Suzuki J., Abe K., Matsui T., Honda T., Yasukawa K., Takanashi J.I., et al.  Kawasaki disease shock syndrome in Japan and comparison with multisystem inflammatory syndrome in children in European countries. Front Pediatr. 2021;9</Citation>
        </Reference>
        <Reference>
          <Citation>Baba T., Maruyama T., Katsuragi S., Maeda K., Kogaki S. Multisystem inflammatory syndrome associated with SARS-CoV-2 in a Japanese girl. Pediatr Int. 2021 doi: 10.1111/ped.14704.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ped.14704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uchida M., Kashima Y., Mochizuki K., Sakamoto H., Mori K., Ebisawa S., et al.  Multisystem inflammatory syndrome in children - a new syndrome complicated with acute heart failure following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Circ J. 2021;85:948–952.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33980782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takasago S., Sakai A., Sugiyama M., Mizokami M., Hamada H., Ishizaka Y., et al.  Case report: changes in cytokine kinetics during the course of disease in a Japanese patient with multisystem inflammatory syndrome in children. Front Pediatr. 2021;9</Citation>
        </Reference>
        <Reference>
          <Citation>Fukuda S., Kaneta M., Miyake M., Ohya T., Miyakawa K., Iwamoto M., et al.  A case of multisystem inflammatory syndrome in children in a Japanese boy: with discussion of cytokine profile. Mod Rheumatol Case Rep. 2021;5:442–447.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33904379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim S.H., Song E.S., Yoon S., Eom G.H., Kang G., Cho Y.K. Serum ferritin as a diagnostic biomarker for Kawasaki disease. Ann Lab Med. 2021;41:318–322.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7748097</ArticleId>
            <ArticleId IdType="pubmed">33303717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mizuta M., Shimizu M., Inoue N., Kasai K., Nakagishi Y., Takahara T., et al.  Serum ferritin levels as a useful diagnostic marker for the distinction of systemic juvenile idiopathic arthritis and Kawasaki disease. Mod Rheumatol. 2016;26:929–932.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27433933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Otar Yener G., Paç Kısaarslan A., Ulu K., Atalay E., Haşlak F., Özdel S., et al.  Differences and similarities of multisystem inflammatory syndrome in children, Kawasaki disease and macrophage activating syndrome due to systemic juvenile idiopathic arthritis: a comparative study. Rheumatol Int. 2021 doi: 10.1007/s00296-021-04980-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00296-021-04980-7</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ravelli A., Minoia F., Davì S., Horne A., Bovis F., Pistorio A., et al.  Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European league against rheumatism/American College of rheumatology/paediatric rheumatology international trials organisation collaborative initiative. Ann Rheum Dis. 2016;75:481–489. 2016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26865703</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kwak E.L., Larochelle D.A., Beaumont C., Torti S.V., Torti F.M. Role for NF-kappa B in the regulation of ferritin H by tumor necrosis factor-alpha. J Biol Chem. 1995;270:15285–15293.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7797515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jinkawa A., Shimizu M., Nishida K., Kaneko S., Usami M., Sakumura N., et al.  Cytokine profile of macrophage activation syndrome associated with Kawasaki disease. Cytokine. 2019;119:52–56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30877950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diorio C., Henrickson S.E., Vella L.A., McNerney K.O., Chase J., Burudpakdee C., et al.  Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2. J Clin Invest. 2020;130:5967–5975.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7598044</ArticleId>
            <ArticleId IdType="pubmed">32730233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mori M., Hara T., Kikuchi M., Shimizu H., Miyamoto T., Iwashima S., et al.  Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Sci Rep. 2018;8:1994.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5792468</ArticleId>
            <ArticleId IdType="pubmed">29386515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gustine J.N., Jones D. Immunopathology of hyperinflammation in COVID-19. Am J Pathol. 2021;191:4–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7484812</ArticleId>
            <ArticleId IdType="pubmed">32919977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cole L.D., Osborne C.M., Silveira L.J., Rao S., Lockwood J.M., Kunkel M.J., et al.  IVIG compared to IVIG plus infliximab in multisystem inflammatory syndrome in children. Pediatrics. 2021 doi: 10.1542/peds.2021-052702.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1542/peds.2021-052702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abdel-Haq N., Asmar B.I., Deza Leon M.P., McGrath E.J., Arora H.S., Cashen K., et al.  SARS-CoV-2-associated multisystem inflammatory syndrome in children: clinical manifestations and the role of infliximab treatment. Eur J Pediatr. 2021;180:1581–1591.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7810600</ArticleId>
            <ArticleId IdType="pubmed">33452570</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gruber C.N., Patel R.S., Trachtman R., Lepow L., Amanat F., Krammer F., et al.  Mapping systemic inflammation and antibody responses in multisystem inflammatory syndrome in children (MIS-C) Cell. 2020;183:982–995.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7489877</ArticleId>
            <ArticleId IdType="pubmed">32991843</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
